English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/143552
Título

Lung cancer in 2013: state of the art therapy for metastatic disease.

AutorShepherd, Frances A.; Bunn, Paul A.; Paz-Ares, Luis
Fecha de publicación2013
EditorAmerican Society of Clinical Oncology
CitaciónAmerican Society of Clinical Oncology educational book: 339-346 (2013)
ResumenLung cancer is the leading worldwide cause of cancer death and the majority of patients present with metastatic stage IV disease. At diagnosis, clinical, histologic, and molecular features must be considered in therapeutic decision-making for systemic therapy. Molecular testing for at least epidermal growth factor receptor (EGFR) and ALK should be performed in all patients before therapy. Platinum doublet chemotherapy may be considered for “fit” patients who do not have a molecular driver genetic abnormality. Bevacizumab can be considered for addition to the doublet in patients with nonsquamous cancers who have no contraindications. A pemetrexed combination is considered only in nonsquamous histology. Patients with EGFR mutations or ALK fusions should be treated with erlotinib or crizotinib, respectively, even in patients with tumor-related poor performance. The tyrosine-kinase inhibitors (TKIs) may be continued until multisite, symptomatic progression. For patients initially treated with a platinum doublet, maintenance chemotherapy with pemetrexed, erlotinib, gemcitabine, or possibly docetaxel is an option with selection based on clinical features, histology, type of initial therapy, and response to first-line therapy.
Versión del editorhttp://doi.org/10.1200/EdBook_AM.2013.33.339
URIhttp://hdl.handle.net/10261/143552
DOI10.1200/EdBook_AM.2013.33.339
Identificadorese-issn: 1548-8756
issn: 1548-8748
Aparece en las colecciones: (IBIS) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.